Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Qingdao Central Hospital
- Target Recruit Count
- 147
- Registration Number
- NCT02959749
- Locations
- ๐จ๐ณ
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Chul Kim
- Target Recruit Count
- 10
- Registration Number
- NCT02954523
- Locations
- ๐บ๐ธ
John Theurer Cacner Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
๐บ๐ธGeorgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT02917993
- Locations
- ๐บ๐ธ
Valley Hospital, 223 N Van Dien Avenue, Ridgewood, New Jersey, United States
๐บ๐ธWest Virginia University Cancer Institute, 1 Medical Center Drive, Morgantown, West Virginia, United States
๐บ๐ธUniversity of Texas -MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, United States
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2022-09-15
- Target Recruit Count
- 156
- Registration Number
- NCT02856893
- Locations
- ๐ซ๐ท
CHU de Brest, Brest, France
๐ต๐ฑMedical University of Gdansk, Gdansk, Poland
๐ซ๐ทInstitut Paoli-Calmettes, Marseille, France
Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 22
- Registration Number
- NCT02841579
- Locations
- ๐ช๐ธ
MedSIR Investigative Site, Valencia, Spain
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT02803203
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering commack, Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Westchester, Harrison, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-03
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 29
- Registration Number
- NCT02789345
- Locations
- ๐ช๐ธ
Hospital Universitario Ramon y Cajal, Madrid, Spain
๐จ๐ณFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Chonnam National University Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT02769286
- Locations
- ๐ฐ๐ท
Chonnam National University Hwasun Hospital, Hwasun, Jeonnam, Korea, Republic of
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT02759835
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- ๐ฌ๐ง
Royal Devon and Exeter Hospital, Exeter, United Kingdom
๐ฌ๐งUniversity Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
๐ฌ๐งQueen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.